Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: NetraMark Holdings Inc.

Market Cap 7.42Cr 5.25Cr 4.57Cr 4.22Cr 3.97Cr 494.77Cr 7.47Cr 50Cr 19Cr 243.83Cr 20Cr 19Cr 845.12Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 7.42Cr 5.25Cr 4.57Cr 4.22Cr 3.97Cr 494.77Cr 7.47Cr 50Cr 19Cr 243.83Cr 20Cr 19Cr 845.12Cr EV / Sales 2026 *
185x
EV / Sales 2027 * -
Free-Float
89.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 5.29Cr
+0.14%-2.65%-20.87%+12.41% 2,81500Cr
-1.63%-1.75%-7.98%+715.64% 31TCr
+14.20%+22.46%+291.79%+907.90% 12TCr
+1.14%+2.56%+32.59%+69.26% 11TCr
-0.95%-0.08%-3.73%+4.69% 8.84TCr
-1.39%-4.88%+71.33%+130.45% 8.07TCr
-0.15%+6.40%-41.44%+48.95% 5.56TCr
+5.65%+13.66%+1.07%+73.38% 4.23TCr
+7.50%+18.85%-49.64%+23.75% 3.44TCr
Average +2.41%+5.83%+30.34%+220.71% 40.66TCr
Weighted average by Cap. +0.52%-2.39%-5.60%+108.07%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.67Cr 4L 27.11L 10.53L 1.32Cr 10.65L 10.42L 4.57Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!